Nanoviricides, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
AMEX
NanoViricides reports reduced quarterly net loss and significant progress in its broad-spectrum antiviral drug NV-387, including Phase II approval for MPox, while addressing going concern doubts with recent capital raises.
AMEX
NanoViricides, Inc. announces its Q3 2025 financial results, highlighting progress in clinical trials for NV-387 and expansion of its antiviral drug pipeline.
AMEX
NanoViricides, Inc. announces its financial results for the quarter ended December 31, 2024, and provides updates on the clinical development of its lead drug candidate, NV-387, targeting multiple viral infections.
AMEX
NanoViricides reported a net loss of $3.13 million for the quarter ended September 30, 2024, while advancing its lead drug candidate, NV-387, towards Phase II clinical trials for RSV and MPox.
AMEX
10-Q: NanoViricides Reports Q3 2024 Results, Highlights Progress in Broad-Spectrum Antiviral Development
NanoViricides reports its Q3 2024 financial results and provides an update on its clinical development programs, particularly highlighting the completion of a Phase 1a/1b trial for its lead drug candidate NV-387.
AMEX
NanoViricides reports its second quarter results, showcasing advancements in its clinical trials for NV-CoV-2 and the broad-spectrum antiviral potential of NV-387.